Early Access — free while we kick the tires
EdgarHawk

Vacirca Jeff L

Director

Director

Latest: Director buying · May 2026

1 filing analyzed · 1 company · Latest 2026-05-12

Never miss a filing from Vacirca Jeff L

Watch this insider and we'll alert you the moment they file — at any company.

Companies

Company Buys Sells Direction
Caris Life Sciences, Inc. CAI 1 0 Net buying

Activity

May 2026
high
Buy
31,050 shares
$501,426
Significance 6/10

Director Vacirca Jeff L purchases 31,050 shares at $16.15, doubling his stake while stock trades well below 52-week highs.

Director Jeff Vacirca is making his second open-market purchase in the past two years, this time acquiring a substantial block that nearly doubles his holdings. The purchase occurs while the stock trades significantly below its 52-week high, having declined notably over the past three months. Vacirca's prior purchase history shows strong subsequent returns, with all prior buys resulting in gains within 90 days, suggesting he has demonstrated timing acuity on previous entries. However, the company remains unprofitable despite strong revenue growth, creating a mixed backdrop: the business is expanding rapidly, but profitability remains elusive. For a director without officer-level operational responsibilities to commit this level of capital at a depressed price point is noteworthy, though the unprofitable fundamentals suggest he is buying into a turnaround story rather than capitalizing on an already-stable business.

Related insiders